Navigation Links
Actinium Pharmaceuticals Appoints Corey Sohmer As Vice President Of Finance And Business Development
Date:9/18/2013

NEW YORK, Sept. 18, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing  innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the appointment of Corey Sohmer to the position of Vice President of Finance and Business Development.  Mr. Sohmer will be responsible for directing Actinium's accounting, finance and investor relations functions as well as supporting capital raising and business development activities.

"Corey has a broad financial background in the biotech industry. He brings leadership experience relevant to all key aspects of Actinium's corporate development, including financing, accounting, investor relations and public reporting," said Kaushik J. Dave, Ph.D., MBA, President and CEO of Actinium.  "Corey will be an extremely valuable addition to the Actinium team as we continue to progress the Company's lead candidates Iomab-B and Actimab-A."

"I am excited to join the Company at a pivotal point in its growth and look forward to contributing to its future success," said Mr. Sohmer.  Prior to joining Actinium, Mr. Sohmer served in a variety of core finance and business development functions over the span of twelve years at three NASDAQ listed biopharmaceutical companies.  Most recently, Mr. Sohmer was the Director Corporate Finance at Cyclacel Pharmaceuticals, Inc. for six years.   Before joining Cyclacel, he was the Senior Director of Financial Planning and External Reporting at EpiCept Corporation and Manager of Finance and Business Development at Pharmos Corporation.  He has more than 20 years of finance and accounting experience.  Mr. Sohmer holds a Masters in Business Administration and a Bachelors of Science degree in Accounting from Bentley University.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) is a New York based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers.  Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha emitting actinium-225 and bismuth-213 radiopharmaceuticals in conjunction with monoclonal antibodies.  The Company also develops other radiopharmaceuticals for select applications.

For more information:
Visit our web site www.actiniumpharmaceuticals.com

Media:
Dennis S. Dobson Jr.
Tel:  (203) 258-0159
Email: dennisdobsonjr@dobsonmediagroup.com

Contact:
Actinium Pharmaceuticals, Inc.
Investor/Media Relations: Corey Sohmer, (646) 459-4201
E-mail: ir@actiniumpharmaceuticals.com

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actinium Pharmaceuticals Appoints Kaushik J. Dave, Ph.D., MBA As President, Chief Executive Officer And Director
2. Actinium Pharmaceuticals Clinical Results Featured at a United Nations Forum
3. Actinium Pharmaceuticals, Inc. Receives $3.5m from Exercise of Warrants
4. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
5. Actinium Pharmaceuticals, Inc. Receives Notice of Patent Allowance for a Key Application
6. Cactus Ventures, Inc. Changes Name to Actinium Pharmaceuticals, Inc.
7. Actinium Pharmaceuticals, Inc. To Present at the 15th Annual BIO CEO Investor Conference
8. Actinium Pharmaceuticals to Present at EMIT Targeted Radiotherapy Conference
9. University of Pennsylvania joins Actinium Pharmaceuticals Multicenter Actimab-A Trial
10. Additional Clinical Data from Two Trials on Actinium Pharmaceuticals Iomab-B to be Presented at American Society of Hematology (ASH) Annual Meeting
11. Actinium Pharmaceuticals Sponsors Webinar on Clinical Use of Alpha Immunotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Markets has announced the addition of the "Endodontic Supplies - Global Strategic ... , ... for Endodontic Supplies in US$ Thousand. The report provides separate comprehensive analytics for ... Europe , Asia-Pacific , Latin America ... provided for the period 2015 through 2022. Also, a six-year historic analysis is ...
(Date:12/8/2016)... , Dec. 8, 2016   TriNetX ... Nationwide Children,s Hospital signed a membership ... accelerate the development of new cures. ... representing over 57 million patients globally, biopharmaceutical companies ... together to improve protocol design, site selection, patient ...
(Date:12/8/2016)... Quebec , Dec. 8, 2016  Valeant ... and TSX: VRX) ("Valeant") today announced positive results ... clinical study to assess the safety and efficacy ... the treatment of plaque psoriasis. ... subjects with moderate to severe psoriasis, IDP-118 showed ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 2016 , ... After enjoying record-breaking attendance at its last ... 33rd Annual Issues & Research Conference, March 2-3, 2017, at the Westin ... is “Persistent Challenges and New Opportunities: Using Research to Accelerate the Dialogue." 2016 ...
(Date:12/8/2016)... , ... December 08, 2016 , ... CURE Media Group, ... and advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat lung ... announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored to team up ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... gives development continuity to its innovative Unified Instance Manager architecture, meeting the ... addition, this new version optimizes the unattended auto-dialing system without agents, Presence ...
(Date:12/8/2016)... City, Ga (PRWEB) , ... December 08, 2016 ... ... moving as soon after surgery as possible. With this in mind, SIGVARIS has ... thrombosis (DVT or blood clot) during bed rest and provide the benefits of ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Dan ... headquartered in Jefferson County, is announcing the launch of a charity drive to ... number of homeless women and children in Birmingham has grown steadily since the ...
Breaking Medicine News(10 mins):